[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 2005

Intralesional Immunotherapy for Genital Warts

Arch Dermatol. 2005;141(12):1606-1607. doi:10.1001/archderm.141.12.1606

Intralesional immunotherapy employing skin test (recall) antigens derived from mumps, Candida, and Trichophyton is an effective and safe treatment for verruca vulgaris and verruca plana.1,2 In adults, we have shown individual treated wart response rates of 60% to 74% (saline control, 22%) and complete clearing of uninjected anatomically distinct and distant warts in 49% to 71% (saline control, 16%). In children with treatment-resistant warts (2 modalities), complete response rates were 47% and 34%, respectively.3